首页> 美国卫生研究院文献>Blood >Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

【2h】

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

机译：达沙替尼可克服KIR2DS1对新诊断的慢性粒细胞白血病患者的不良预后影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Blood
作者
Sara Ali; Ruhena Sergeant; Stephen G. OBrien; Letizia Foroni; Corinne Hedgley; Gareth Gerrard; Dragana Milojkovic; Kate Stringaris; Ahmad Khoder; Abdullah Alsuliman; Maria Gilleece; Ian H. Gabriel; Nichola Cooper; John M. Goldman; Jane F. Apperley; Richard E. Clark; David Marin; Katayoun Rezvani;
展开▼
作者单位

展开▼
年(卷),期 -1(120),3
年度 -1
页码 697–698
总页数 4
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia [J] . AliS., SergeantR., OBrienS.G., Blood: The Journal of the American Society of Hematology . 2012,第3期

机译：达沙替尼可克服KIR2DS1对新诊断的慢性粒细胞白血病患者的不良预后影响
2. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. [J] . Doggrell SA, Christensen AM Expert opinion on pharmacotherapy . 2011,第1期

机译：是否有比伊马替尼更好的Bcr-Abl激酶抑制剂用于慢性粒细胞白血病？ Saglio G，Kim D-W，Issaragrisil S等的评估。尼洛替尼与伊马替尼治疗新诊断的慢性粒细胞白血病。 N Engl J Med 2010; 362：2251-9，and Kantarjian H，Shah NP，Hochhaus A等。达沙替尼与伊马替尼治疗新近诊断的慢性期慢性粒细胞白血病。 N Engl J Med 2010; 362：2260-70。
3. Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [J] . AbbottB.L. Clinical therapeutics . 2012,第2期

机译：达沙替尼：从对伊马替尼耐药或不耐受的慢性粒细胞白血病患者的治疗到新诊断的慢性期慢性粒细胞白血病患者的治疗
4. A new FISH Signals Fusion Detection approach for diagnosing Chronic Myeloid Leukemia [C] . Ashraf AbdelRaouf International Conference on Computer Engineering and Systems . 2019

机译：一种新的FISH信号融合检测方法，用于诊断慢性粒细胞白血病
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients [O] . Andreas Hochhaus, Hagop Kantarjian -1

机译：达沙替尼治疗慢性粒细胞白血病（CML）的发展：从初步研究到在新诊断患者中的应用
7. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib [O] . D Marin, I H Gabriel, S Ahmad, 2011

机译：Kir2DS1基因型预测新诊断培养的慢性骨髓白血病患者的完全细胞遗传学反应和生存率

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

著录项

相似文献

相关主题

期刊订阅